What smart money is saying about Medpace
5 funds in our archive have pitched Medpace, most recently Optimist Fund in September 2025.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.
Get an email when a fund buys, sells or pitches it
Fund signal · last 12 months
9 lettersToo few moves on Medpace yet for a clear signal
Moves described in fund letters in our archive. A sentence published word for word by several funds of one house in the same quarter counts once.
Position history
Between Q4 2024 and Q3 2026, 14 fund letters reported a position in Medpace, with 4 buys (opened or added) and 3 sells (trimmed or exited).
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 2 | 0 |
| Q2 2026 | 1 | 0 | 0 | 0 |
| Q1 2026 | 1 | 1 | 0 | 0 |
| Q4 2025 | 3 | 0 | 0 | 0 |
| Q3 2025 | 2 | 1 | 0 | 1 |
| Q2 2025 | 1 | 1 | 0 | 2 |
| Q1 2025 | 1 | 1 | 0 | 1 |
| Q4 2024 | 1 | 0 | 1 | 1 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 14 positions · 7 moves
- September 2026
“Medpace, a clinical research organization, reported revenue growth of more than 17% and a 28% increase in net new business awards, then raised revenue and earnings guidance, evidence that biotechnology demand remained healthy despite broader uncertainty around life sciences funding.”
Medpace - September 2026
“Finally, we sold Victory Capital and trimmed Medpace because both had appreciated to market capitalizations increasingly outside the range we consider appropriate for a true small cap portfolio.”
Medpace - September 2026
“HCA Healthcare and Medpace also contributed within health care, as did Mastercard in financials.”
Medpace - TrimmedSpyglass Growth StrategySeptember 2026
“During the third quarter, the positions that were most significantly trimmed were Snowflake, Illumina, and Medpace.”
Medpace - HoldsOptimist FundJune 2026
Listed in Optimist Fund’s reported holdings.
Medpace - AddedKNA CapitalFebruary 2026
“After trimming our position in Medpace in January, I added back to it following a disappointing earnings result that I believe is temporary in nature.”
Medpace - December 2025
“Another strong stock was that of MedPace Holdings, Inc. (MEDP).”
Medpace - December 2025
Listed in Wasatch Small Cap Growth Fund’s reported holdings.
Medpace - December 2025
“Medpace Holdings, Inc. 3.0%”
Medpace - September 2025
“Notable positive contributors for the Fund were Medpace Holdings, Inc., AAR, and nVent Electric. Medpace outperformed due to an improvement in clinical trial cancellation trends within its pipeline.”
Medpace - AddedHeadwaters CapitalSeptember 2025
“Top Contributor: Medpace (“MEDP”) +64%. Medpace had a phenomenal quarter highlighted by strong bookings in a difficult biotech funding environment. The strong bookings growth was enhanced by aggressive share repurchases as the company has taken advantage of stock price weakness to repurchase 10% of shares outstanding over the last year. I wrote about MEDP in detail as part of the Q3 ’24 letter when the stock was the largest detractor.”
Medpace - New positionMadison Mid Cap FundJune 2025
“We added one new investment in the quarter, Medpace Holdings.”
Medpace - New positionVulcan VPMarch 2025
“We purchased three positions during the quarter: Medpace Holdings Inc., Stanley Black & Decker, and TPG Inc.”
Medpace - ExitedIthaka groupDecember 2024
“Transactions During the quarter we initiated one new position in Arista Networks (ANET) and eliminated both Lululemon (LULU) and Medpace (MEDP).”
Medpace
Fund coverage · 5 theses
- Optimist FundSeptember 2025
Medpace is a leading CRO that achieves consistent growth and exceptional margins by focusing on serving small and mid-sized biotech companies with a disciplined, full-service approach under the leadership of its founder-CEO.
Read the full thesis - Mairs and Power Growth FundJune 2025
Medpace Holdings is a leading contract research organization specializing in clinical trials for small and mid-sized biotech and pharmaceutical companies, positioned well in a growing market with a strong competitive advantage.
Read the full thesis - Madison Mid Cap FundJune 2025
Medpace Holdings is a rapidly growing contract research organization focused on clinical trial services for small biotech companies, led by a committed founder and with significant growth potential despite current market challenges.
Read the full thesis - VulcanMarch 2025
Medpace Holdings is a strong clinical CRO that offers full-service drug development solutions, primarily catering to small and midsized biotech firms, and is expected to return to double-digit growth after a flat year in 2025.
Read the full thesis - Giverny CapitalDecember 2024
Medpace Holdings is a leading clinical trial provider for early-stage biopharma companies
Read the full thesis
Read every full thesis on Medpace
Read all 5 theses in full, with each fund's reasoning, and get unlimited access to the archive.
View plans→